Nathalie Clément, Ph.D.
Associate Director Powell Gene Therapy Center Vector Core
- Director, AAV Core Facility, 2003-2008, Mount Sinai School of Medicine, New York, NY
- Post-doctoral fellowship, 2001-2003, Mount Sinai School of Medicine, New York, NY
- Ph.D, 2001, University Libre of Brussels, Brussels, Belgium
- B.S., 1995, University Libre of Brussels, Brussels, Belgium
Dr. Clément as Associate Director is in charge of the overall supervision of the AAV Vector Core production facility, located in the Department of Pediatrics, Powell Gene Therapy Center. More particularly she is involved in Process & Development of new methods for large-scale AAV vector production and purification. These activities are performed in tight collaboration with the Human Application Laboratory to ensure efficient and swift transfer of these methodologies to GMP settings for clinical grade preparations.
Dr. Clément gained an extensive knowledge in both the Gene Therapy and Parvovirus fields during her Ph.D work and post-doctoral fellowship, with a special emphasis in the development of AAV-based vectors for Gene Therapy applications. She ran a core facility in the Mount Sinai Hospital where she was in charge of supervising the development of many new AAV-based vectors including their production, purification and quality control assays. She was recently recruited to the PGTC where she continues to dedicate her research to the development of AAV vectors for research and clinical projects.
Additional publications can be found in PubMed.
- Ward P, Clément N, Linden M. Cis effects in AAV2 replication. 2007, Journal of Virology 81(18): 9976-9989
- Hirosue S, Senn K, Clément N, Nonnenmacher M, Gigout L, Linden M, Weber T. Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction. 2007, Virology 367(1): 10-18
- Glauser DL, Strasser R, Laimbacher AS, Saydam O, Clément N, Linden RM, Ackermann M, Fraefel C. Live covisualization of competing adeno-associated virus and herpes simplex virus type 1 DNA replication: molecular mechanisms of interaction. 2007, Journal of Virology 81(9): 4732-4743
- Gigout Laure, Rebollo Patricia, Clément Nathalie, Warrington Jr. Kenneth H, Muzyczka Nicholas, Linden Michael R, Weber Thomas. 2005, Molecular Therapy 11(6): 856-865
- Zhang Nan, Clément Nathalie, Chen Dongmei, Fu Shuang, Zhang Haojiang, Rebollo Patricia, Linden Michael, Bromberg Jonathan. Transduction of pancreatic islets with pseudotyped adeno-associated virus: Effect of viral capsid and genome conversion. 2005, Transplantation 80(5): 683-690
- El Bakkouri Karim and Servais, Charlotte, Clément Nathalie, Siew Chiat Cheong, Franssen Jean-Denis, Velu Thierry and Brandenburger Annick. In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA. 2004, The journal of Gene Medicine, 6
- Siew Chiat Cheong, Nathalie Clément, Thierry Velu and Annick Brandenburger. A novel method for the titration of recombinant virus stocks by ELISPOT assay. 2003, Journal of Virological Methods, 109(2): 119-124
- Clément Nathalie, Velu Thierry, and Annick Brandenburger. Construction and production of oncotropic vectors derived from MVM(p), that share reduced sequence homology with helper plasmids. 2002, Cancer Gene Therapy 9 : 762-770.
- Clément Nathalie, Avalosse Bernard, El Bakkouri Karim, Velu Thierry, and Annick Brandenburger. Cloning and sequencing of defective particles derived from the autonomous parvovirus minute virus of mice for the construction of vectors with minimal cis-acting sequences. 2001, Journal of Virology 75(3): 1284-1293
- Fragkos M, Breuleux M, Clément N, Beard P. Recombinant adeno-associated viral vectors are deficient in provoking a DNA damage response. 2008, Journal of Virology 82(15): 7379-7387